Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah M Jones

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|February 2, 2024
Physiologically-based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patientsMagali Amiel, Alice Ke, Steven P Gelone, et al.
Clinical Pharmacology and Therapeutics|November 26, 2024
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug InteractionsCornelius Cilliers, Eleanor Howgate, Hannah M Jones, et al.
British Journal of Clinical Pharmacology|June 22, 2011
Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis CHannah M Jones, Phylinda L S Chan, Piet H van der Graaf, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 30, 2025
Real-world application of physiologically based pharmacokinetic models in drug discoveryLaura G A Santos, Swati Jaiswal, Kuan-Fu Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 20, 2023
Real-world application of PBPK in drug discoveryLaura G A Santos, Swati Jaiswal, Kuan-Fu Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 6, 2011
Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonistPeter J Bungay, Sarah Tweedy, David C Howe, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 15, 2026
How can we overcome the pharmacokinetic challenges posed when conducting complex DDI studies?Iain Gardner, Eva Gil Berglund, Hannah M Jones, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 4, 2025
Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic ModelingSwati Jaiswal, Nikunjkumar K Patel, Hannah M Jones, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 25, 2010
Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment modelShinji Yamazaki, Judith Skaptason, David Romero, et al.
Interface Focus|January 16, 2014
Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacologyNeil Benson, Tomomi Matsuura, Sergey Smirnov, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
CPT: Pharmacometrics & Systems Pharmacology|February 2, 2024
Physiologically-based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patientsMagali Amiel, Alice Ke, Steven P Gelone, et al.
Clinical Pharmacology and Therapeutics|November 26, 2024
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug InteractionsCornelius Cilliers, Eleanor Howgate, Hannah M Jones, et al.
British Journal of Clinical Pharmacology|June 22, 2011
Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis CHannah M Jones, Phylinda L S Chan, Piet H van der Graaf, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 30, 2025
Real-world application of physiologically based pharmacokinetic models in drug discoveryLaura G A Santos, Swati Jaiswal, Kuan-Fu Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 20, 2023
Real-world application of PBPK in drug discoveryLaura G A Santos, Swati Jaiswal, Kuan-Fu Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 6, 2011
Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonistPeter J Bungay, Sarah Tweedy, David C Howe, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 15, 2026
How can we overcome the pharmacokinetic challenges posed when conducting complex DDI studies?Iain Gardner, Eva Gil Berglund, Hannah M Jones, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 4, 2025
Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic ModelingSwati Jaiswal, Nikunjkumar K Patel, Hannah M Jones, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 25, 2010
Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment modelShinji Yamazaki, Judith Skaptason, David Romero, et al.
Interface Focus|January 16, 2014
Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacologyNeil Benson, Tomomi Matsuura, Sergey Smirnov, et al.
Pageof 10